Quest Diagnostics Inc vs Williams-Sonoma, Inc. — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Williams-Sonoma, Inc. trades at $241.78 (market cap $28.15B). The key difference: Quest Diagnostics Inc and Williams-Sonoma, Inc. are close in size by market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Williams-Sonoma, Inc. for 59 Days on average.
| DGX | WSM | |
|---|---|---|
Market Cap | $25.48B | $28.15B |
Volume | 941,866 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $251.81 |
52-Week Low | $173.49 | $168.64 |
Typical Hold Time | 56 Days | 59 Days |
Enterprise Value | $31.23B | $28.65B |
Dividend Yield | 1.49% | 1.27% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
Williams-Sonoma (WSM) trades at $239.00, down 0.61% on the day, near its pivot point of $239 with bullish moving average signals. The company demonstrates strong profitability with a 14.73% net income margin and 54.96% ROE, supported by three consecutive quarterly earnings beats. Recent news highlights market share gains and margin expansion through reduced discounting, with a new Pottery Barn collaboration and store openings fueling growth.
The outlook remains positive with a consensus price target of $246.31 offering 3% upside, though risks include housing market sensitivity and high valuation multiples. Earnings growth and disciplined cost control position WSM for continued outperformance, but investors should monitor competitive pressures and macroeconomic headwinds affecting consumer spending.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →